S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

ACADIA Pharmaceuticals Stock Forecast, Price & News

+0.22 (+1.57%)
(As of 06/29/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.84 million shs
Average Volume
2.06 million shs
Market Capitalization
$2.30 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Stock Forecast (MarketRank)

Overall MarketRank

2.80 out of 5 stars

Medical Sector

41st out of 1,432 stocks

Pharmaceutical Preparations Industry

13th out of 685 stocks

Analyst Opinion: 4.2Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -
ACADIA Pharmaceuticals logo

About ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

ACAD Stock News Headlines

Nasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares Plummet
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
18 Analysts


Net Income
$-167.87 million
Pretax Margin


Sales & Book Value

Annual Sales
$484.14 million
Book Value
$3.36 per share


Free Float
Market Cap
$2.30 billion

ACADIA Pharmaceuticals Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ACADIA Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View analyst ratings for ACADIA Pharmaceuticals
or view top-rated stocks.

What is ACADIA Pharmaceuticals' stock price forecast for 2022?

18 brokers have issued 12 month price objectives for ACADIA Pharmaceuticals' shares. Their ACAD stock forecasts range from $10.00 to $35.00. On average, they predict ACADIA Pharmaceuticals' stock price to reach $24.63 in the next year. This suggests a possible upside of 73.2% from the stock's current price.
View analysts' price targets for ACADIA Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has ACADIA Pharmaceuticals' stock performed in 2022?

ACADIA Pharmaceuticals' stock was trading at $23.34 at the beginning of the year. Since then, ACAD shares have decreased by 39.1% and is now trading at $14.22.
View the best growth stocks for 2022 here

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for ACADIA Pharmaceuticals

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings results on Wednesday, May, 4th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.21. The biopharmaceutical company earned $115.47 million during the quarter, compared to analysts' expectations of $122.22 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 40.52% and a negative net margin of 43.50%. ACADIA Pharmaceuticals's quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.42) earnings per share.
View ACADIA Pharmaceuticals' earnings history

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $510.00 million-$560.00 million, compared to the consensus revenue estimate of $540.68 million.

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the following people:

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals CEO Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among ACADIA Pharmaceuticals' employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $14.22.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $2.30 billion and generates $484.14 million in revenue each year. The biopharmaceutical company earns $-167.87 million in net income (profit) each year or ($1.330010) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

ACADIA Pharmaceuticals employs 514 workers across the globe.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at [email protected], or via fax at 858-558-2872.

This page (NASDAQ:ACAD) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.